A carregar...
Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm classified according to the 2016 revision of World Health Organization Classification of Tumors and Haematopoietic and Lymphoid Tissue. Ruxolitinib is an oral inhibitor of Janus kinase approved in the USA for the treatment of intermediate...
Na minha lista:
| Publicado no: | Ther Clin Risk Manag |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5315213/ https://ncbi.nlm.nih.gov/pubmed/28243106 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S121683 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|